Last reviewed · How we verify
D759, D150
At a glance
| Generic name | D759, D150 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes (PHASE3)
- A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150 (PHASE1)
- Study to Evaluate the Safety and Pharmacokinetics of CKD-379 (PHASE1)
- Pharmacokinetics and Safety/Tolerability of CKD-379 (PHASE1)
- Pharmacokinetics and Safety/Tolerability Profile of CKD-379 (PHASE1)
- A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects (PHASE1)
- Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D759, D150 CI brief — competitive landscape report
- D759, D150 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI